 | • レポートコード：MRC2305C103 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に742.67百万ドルであった世界の鎌状赤血球貧血検査＆スクリーニング市場規模が、2022年には832.68百万ドルに成長し、その後年平均13.22％拡大して2027年には1,565.01百万ドルに達すると予測しています。本調査資料では、鎌状赤血球貧血検査＆スクリーニングの世界市場について総合的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別（ヘモグロビン電気泳動、高速液体クロマトグラフィー（HPLC）、ポイントオブケア検査）分析、年齢層別（成人、新生児、1～25歳）分析、セクター別（企業研究所、政府研究所、民間研究所、官民パートナーシップ）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめました。なお、本書内の企業情報には、Agios Pharmaceuticals, Inc.、Anamol Laboratories Pvt. Ltd.、Atlas Medical GmbH、Bio Lab Diagnostics (I) Private Limited、Bio-Rad Laboratories, Inc.、Biomedomics Inc.、Bluebird bio, Inc.、Calibre Scientific, Inc.、Edvotek Inc.、Hemex Healthなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の鎌状赤血球貧血検査＆スクリーニング市場規模：技術別 - ヘモグロビン電気泳動の市場規模 - 高速液体クロマトグラフィー（HPLC）の市場規模 - ポイントオブケア検査の市場規模 ・世界の鎌状赤血球貧血検査＆スクリーニング市場規模：年齢層別 - 成人における市場規模 - 新生児における市場規模 - 1～25歳における市場規模 ・世界の鎌状赤血球貧血検査＆スクリーニング市場規模：セクター別 - 企業研究所における市場規模 - 政府研究所における市場規模 - 民間研究所における市場規模 - 官民パートナーシップにおける市場規模 ・世界の鎌状赤血球貧血検査＆スクリーニング市場規模：地域別 - 南北アメリカの鎌状赤血球貧血検査＆スクリーニング市場規模 アメリカの鎌状赤血球貧血検査＆スクリーニング市場規模 カナダの鎌状赤血球貧血検査＆スクリーニング市場規模 ブラジルの鎌状赤血球貧血検査＆スクリーニング市場規模 ... - アジア太平洋の鎌状赤血球貧血検査＆スクリーニング市場規模 日本の鎌状赤血球貧血検査＆スクリーニング市場規模 中国の鎌状赤血球貧血検査＆スクリーニング市場規模 インドの鎌状赤血球貧血検査＆スクリーニング市場規模 韓国の鎌状赤血球貧血検査＆スクリーニング市場規模 台湾の鎌状赤血球貧血検査＆スクリーニング市場規模 ... - ヨーロッパ/中東/アフリカの鎌状赤血球貧血検査＆スクリーニング市場規模 イギリスの鎌状赤血球貧血検査＆スクリーニング市場規模 ドイツの鎌状赤血球貧血検査＆スクリーニング市場規模 フランスの鎌状赤血球貧血検査＆スクリーニング市場規模 ロシアの鎌状赤血球貧血検査＆スクリーニング市場規模 ... - その他地域の鎌状赤血球貧血検査＆スクリーニング市場規模 ・競争状況 ・企業情報 |
The Global Sickle Cell Anemia Testing & Screening Market size was estimated at USD 742.67 million in 2021 and expected to reach USD 832.68 million in 2022, and is projected to grow at a CAGR 13.22% to reach USD 1,565.01 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Sickle Cell Anemia Testing & Screening to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), and Point-of-Care Tests. The Hemoglobin Electrophoresis is further studied across Isoelectric focusing. The Point-of-Care Tests is further studied across Lateral Flow Immunoassay and Paper Based Rapid Diagnostics.
Based on Age Group, the market was studied across Adult Screening, Newborn Screening, and Years 1 to 25.
Based on Sector, the market was studied across Corporate Labs, Government Labs, Private Labs, and Public-Private-Partnerships.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Illinois, Indiana, Iowa, Kansas, Minnesota, Nebraska, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Sickle Cell Anemia Testing & Screening market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Sickle Cell Anemia Testing & Screening Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Sickle Cell Anemia Testing & Screening Market, including Agios Pharmaceuticals, Inc., Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Biomedomics Inc., Bluebird bio, Inc., Calibre Scientific, Inc., Edvotek Inc., Hemex Health, HiMedia Laboratories, Laboratory Corporation of America Holdings, Maternova Inc., PerkinElmer, Inc., PicnicHealth, Quest Diagnostics Incorporated, Silver Lake Research Corporation, Streck, Inc., Thermo Fisher Scientific Inc., and Ulta Lab Tests, LLC.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Sickle Cell Anemia Testing & Screening Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Sickle Cell Anemia Testing & Screening Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Sickle Cell Anemia Testing & Screening Market?
4. What is the competitive strategic window for opportunities in the Global Sickle Cell Anemia Testing & Screening Market?
5. What are the technology trends and regulatory frameworks in the Global Sickle Cell Anemia Testing & Screening Market?
6. What is the market share of the leading vendors in the Global Sickle Cell Anemia Testing & Screening Market?
7. What modes and strategic moves are considered suitable for entering the Global Sickle Cell Anemia Testing & Screening Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
5.1.2. Restraints
5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
5.1.3. Opportunities
5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
5.1.4. Challenges
5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
5.2. Cumulative Impact of COVID-19
6. Sickle Cell Anemia Testing & Screening Market, by Technology
6.1. Introduction
6.2. Hemoglobin Electrophoresis
6.3.1. Isoelectric focusing
6.3. High-performance Liquid Chromatography (HPLC)
6.4. Point-of-Care Tests
6.5.1. Lateral Flow Immunoassay
6.5.2. Paper Based Rapid Diagnostics
7. Sickle Cell Anemia Testing & Screening Market, by Age Group
7.1. Introduction
7.2. Adult Screening
7.3. Newborn Screening
7.4. Years 1 to 25
8. Sickle Cell Anemia Testing & Screening Market, by Sector
8.1. Introduction
8.2. Corporate Labs
8.3. Government Labs
8.4. Private Labs
8.5. Public-Private-Partnerships
9. Americas Sickle Cell Anemia Testing & Screening Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Agios Pharmaceuticals, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Anamol Laboratories Pvt. Ltd.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Atlas Medical GmbH
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bio Lab Diagnostics (I) Private Limited
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bio-Rad Laboratories, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Biomedomics Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bluebird bio, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Calibre Scientific, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Edvotek Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Hemex Health
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. HiMedia Laboratories
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Laboratory Corporation of America Holdings
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Maternova Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. PerkinElmer, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. PicnicHealth
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Quest Diagnostics Incorporated
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Silver Lake Research Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Streck, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Thermo Fisher Scientific Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Ulta Lab Tests, LLC
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing